Picture EBD Group Global Partnering Four Events One Price 650x80
Organisation › Details

Immuneering Corporation

Since its launch in February 2008, Immuneering has partnered with leading pharmaceutical companies to accelerate and improve the discovery and clinical development of novel drugs. The Immuneering team applies proprietary computational biology methods and an advanced drug discovery platform to high-throughput molecular data, re-engineering the process by which new medicines are discovered and developed to be faster, less expensive, and more likely to succeed. The company's proprietary drug discovery platform identifies "hits" (the molecular structures that form the basis of new medicines) in a matter of days or weeks, rather than the months or years of target identification and high-throughput screening typically required. This acceleration is made possible by applying artificial intelligence (AI) and other advanced algorithms to high-throughput data, and draws on Immuneering's decade of experience in applying high-throughput data to pharmaceutical R&D. Immuneering's team of experts also provides world-class bioinformatics and computational biology services. *


Period Start 2008-02-01 established
Products Industry drug discovery software
  Industry 2 artificial intelligence (AI) / machine learning (ML)
Person Person Zeskind, Ben (Immuneering 201806 CEO)
Region Region Cambridge, MA
  Country United States (USA)
  Street 245 Main Street
2nd Floor
  City 02142 Cambridge, MA
    Address record changed: 2021-03-28
Basic data Employees n. a.
    * Document for �About Section�: Evotec AG. (11/21/18). "Press Release: Evotec and Immuneering to Collaborate on Artifical Intelligence (“AI”) Driven Ligand Identification for Rare Hereditary Metabolic Diseases". Hamburg & Cambridge, MA.
Record changed: 2021-03-28


Picture EBD Group Connector Personal Networking in Life Sciences 650x80

More documents for Immuneering Corporation

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group ChinaBio Partnerting Forum 2021 651x80

» top